Point72 Asset Management L.P. Has $42.99 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Point72 Asset Management L.P. trimmed its position in shares of BioNTech SE (NASDAQ:BNTX) by 21.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 361,993 shares of the company’s stock after selling 99,718 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.15% of BioNTech worth $42,994,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BNTX. FMR LLC lifted its stake in shares of BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after acquiring an additional 5,598,190 shares during the period. Fred Alger Management LLC acquired a new position in shares of BioNTech in the third quarter worth approximately $59,485,000. Candriam S.C.A. lifted its stake in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares during the period. Braidwell LP acquired a new position in shares of BioNTech in the third quarter worth approximately $29,425,000. Finally, New York State Common Retirement Fund lifted its stake in shares of BioNTech by 457.9% in the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after acquiring an additional 178,981 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and lifted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Berenberg Bank began coverage on BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Finally, Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Trading Down 0.8 %

NASDAQ BNTX opened at $114.70 on Thursday. The company has a market cap of $27.50 billion, a price-to-earnings ratio of -54.62 and a beta of 0.22. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The business has a 50 day moving average price of $113.83 and a 200-day moving average price of $99.12.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 earnings per share. As a group, equities analysts expect that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.